| 0.3745 -0.012 (-3.1%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.5 | 1-year : | 0.59 |
| Resists | First : | 0.43 | Second : | 0.5 |
| Pivot price | 0.35  |
|||
| Supports | First : | 0.31 | Second : | 0.25 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.36 |
| MA(100) : | 0.35 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.6 |
D(3) : | 50.1 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 1.54 | Low : | 0.22 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CODX ] has closed below upper band by 20.4%. Bollinger Bands are 65.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.4 - 0.4 | 0.4 - 0.4 |
| Low: | 0.37 - 0.37 | 0.37 - 0.37 |
| Close: | 0.37 - 0.37 | 0.37 - 0.38 |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Thu, 13 Nov 2025
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 13 Nov 2025
Co-Diagnostics Inc (CODX) Q3 2025 Earnings Call Highlights: Strategic Ventures and Financial ... - Yahoo Finance
Thu, 13 Nov 2025
Co-Diagnostics Reports Third Quarter 2025 Financial Results - PR Newswire
Mon, 03 Nov 2025
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform - PR Newswire
Mon, 03 Nov 2025
Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 5.406e+007 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 112 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.433e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 824.4 % |
| Return on Equity (ttm) | -38 % |
| Qtrly Rev. Growth | 507890 % |
| Gross Profit (p.s.) | -67.22 |
| Sales Per Share | -54.02 |
| EBITDA (p.s.) | 150296 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.51 |
| Dividend | 0 |
| Forward Dividend | 1.71e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|